2024
Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial
Ramakrishnan D, Brüningk S, von Reppert M, Memon F, Maleki N, Aneja S, Kazerooni A, Nabavizadeh A, Lin M, Bousabarah K, Molinaro A, Nicolaides T, Prados M, Mueller S, Aboian M. Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial. American Journal Of Neuroradiology 2024, 45: 475-482. PMID: 38453411, PMCID: PMC11288571, DOI: 10.3174/ajnr.a8189.Peer-Reviewed Original ResearchArea under the curvePediatric gliomasBT-RADSResponse assessmentPartial responseClinical trialsVolumetric analysisReceiver operating characteristic analysisBrain Tumor ReportingReceiver operating characteristic curveModel estimation timeOperating characteristic analysisEvaluate treatment efficacyStable diseasePartial respondersManual volumetric segmentationNo significant differenceSolid tumorsProspective studyTumor ReportingClinical decision-makingTreatment efficacyGliomaSignificant differenceCharacteristic curve
2014
Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting Overall SurvivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply